Revenue, last quarter
$30.3M
−60.3% vs same quarter last year
Net income
$3.9M
−74.4% vs same quarter last year
EPS, diluted
$0.11
−78.8% vs same quarter last year
Operating cash flow
−$9.5M
+65.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $234.6M | −$13.2M |
| FY24 | $91.3M | −$145.2M |
| FY23 | $17.2M | −$163.6M |
| FY22 | $10.3M | −$128.7M |
| FY21 | $63.2M | −$57.8M |
| FY20 | $75M | −$19.9M |
| FY19 | $8M | −$97.3M |
| FY18 | $5M | −$61.7M |
| FY17 | $10M | −$30.1M |
| FY16 | $16.7M | −$4.3M |
| FY15 | $17.6M | −$5.4M |
| FY14 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | 96.7% | −5.6% |
| FY24 | 72.5% | −159.1% |
| FY23 | −958.3% | −953.7% |
| FY22 | −1119.4% | −1251.3% |
| FY21 | −89.9% | −91.5% |
| FY20 | −31.8% | −26.6% |
| FY19 | −1342.9% | −1216.7% |
| FY18 | −1334.4% | −1233.1% |
| FY17 | −287.8% | −300.7% |
| FY16 | −18.1% | −25.5% |
| FY15 | −18.9% | −30.8% |
| FY14 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $19.6M |
| FY24 | −$135.7M |
| FY23 | −$121.6M |
| FY22 | −$74M |
| FY21 | −$47.3M |
| FY20 | −$14.7M |
| FY19 | −$70.3M |
| FY18 | −$49.6M |
| FY17 | −$19.7M |
| FY16 | −$9.1M |
| FY15 | −$9.9M |
| FY14 | - |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $68.6M |
| FY24 | $456K |
| FY23 | $50M |
| FY22 | $0 |
| FY21 | $0 |
| FY20 | - |
| FY19 | - |
| FY18 | $0 |
| FY17 | $0 |
| FY16 | $1K |
| FY15 | $0 |
| FY14 | - |
- Anaptysbio
- Healthcare median
Show the numbers
| Year | Anaptysbio | Healthcare median |
|---|---|---|
| FY25 | −5.6% | −30.6% |
| FY24 | −159.1% | −47% |
| FY23 | −953.7% | −58% |
| FY22 | −1251.3% | −80.4% |
| FY21 | −91.5% | −71.8% |
| FY20 | −26.6% | −62.2% |
| FY19 | −1216.7% | −46.2% |
| FY18 | −1233.1% | −49.6% |
| FY17 | −300.7% | −45.9% |
| FY16 | −25.5% | −36% |
| FY15 | −30.8% | −37.8% |
| FY14 | - | −35.5% |